A new federal partnership with BD will invest $19 billion to expand domestic US manufacturing, operational capacity, and supply chain infrastructure.
RT’s Three Key Takeaways:
- Domestic Manufacturing Expansion: Under a new partnership with the US government, BD plans to invest $19 billion across several years to expand domestic manufacturing, operational capacity, and supply chain infrastructure.
- Increased Consumable Output: The agreement aims to increase US production by approximately 5 billion essential medical consumables annually, raising BD’s share of domestically supplied consumables to approximately 80%, the company announced.
- Supply Chain Security: The partnership is designed to protect critical hospital workflows from global supply shocks by producing 100% of BD needles used in the US from American-made steel and providing relief from future tariffs under Section 232, according to BD.
BD (Becton, Dickinson and Company) has entered into a partnership with the US government to expand domestic production and improve supply chain security for essential medical consumables, according to the company.
The initiative focuses on medical consumables that BD reports are used in roughly 90% of US hospital visits, items that play a foundational role in everyday acute care, vascular access, medication administration, and respiratory procedures.
“This agreement reflects a shared commitment between the US Government and BD to strengthening America’s healthcare infrastructure, expanding US manufacturing capacity and supporting reliable access to essential medical technologies, ultimately building a more resilient healthcare system for the future,” said Tom Polen, chairman, chief executive officer, and president of BD.
Details of the Multi-Billion Dollar Investment
Under the terms of the agreement, BD plans to direct $19 billion into US operations over several years, including capital expenditures, operational enhancements, and supply chain infrastructure.
From that total capital allocation, BD plans to allocate $3 billion specifically toward expanding manufacturing across its strategic domestic production network, the company stated. Key sites identified in the company’s network include facilities in Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Sandy, Utah; El Paso, Texas; Covington, Georgia; Sumter, South Carolina; and Añasco, Puerto Rico.
Through these facility expansions, BD aims to expand end-to-end domestic production by roughly 5 billion essential medical consumables each year, raising the manufacturer’s share of domestically sourced consumables to roughly 80%, according to company figures. Additionally, the company plans to produce 100% of the BD needles used across the US domestically using American-made steel.
Tariff Relief and Healthcare Resilience
The collaborative agreement also includes provisions that grant BD relief from future tariffs administered under Section 232 on covered medical consumables and materials, contingent upon achieving defined program milestones, according to the manufacturer’s statement.
BD says that this regulatory certainty supports long-term production and operational planning as hospital providers work to safeguard against the supply shortages experienced during public health crises and logistics disruptions in recent years. Because official tariff rates, product scope, and implementation dates have not been finalized, BD stated that it is not yet quantifying the financial impact of the partnership.
